Pulmatrix Pre-Tax Profit Margin 2014-2021 | PULM

Pulmatrix pre-tax profit margin from 2014 to 2021. Pre-tax profit margin can be defined as earnings before taxes as a portion of total revenue.
Pulmatrix Pre-Tax Profit Margin Historical Data
Date TTM Revenue TTM Pre-Tax Income Pre-Tax Margin
2021-09-30 $0.01B $-0.02B -316.67%
2021-06-30 $0.01B $-0.02B -244.44%
2021-03-31 $0.01B $-0.02B -172.73%
2020-12-31 $0.01B $-0.02B -153.85%
2020-09-30 $0.01B $-0.02B -161.54%
2020-06-30 $0.01B $-0.01B -140.00%
2020-03-31 $0.01B $-0.02B -190.91%
2017-09-30 $0.00B $-0.03B inf%
2016-12-31 $0.00B $-0.03B inf%
2016-09-30 $0.00B $-0.02B inf%
2016-06-30 $0.00B $-0.03B -2500.00%
2016-03-31 $0.00B $-0.03B -3100.00%
2015-12-31 $0.00B $-0.03B -2700.00%
2015-06-30 $0.00B $-0.03B inf%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.037B $0.013B
Pulmatrix, Inc. is a biopharmaceutical company which is engaged in developing inhaled therapies for serious pulmonary disease. The Company's proprietary product pipeline includes PUR1900, an inhaled anti-fungal for cystic fibrosis, PUR0200, a branded generic for chronic obstructive pulmonary disease which are in different clinical stage. Its technology platform consists of iSPERSE. Pulmatrix, Inc., formerly known as Ruthigen, Inc., is based in Lexington, MA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $125.477B 7.93
Bio-Rad Laboratories (BIO.B) United States $23.034B 46.74
QIAGEN (QGEN) Netherlands $12.874B 21.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.457B 0.00
Arcus Biosciences (RCUS) United States $3.257B 0.00
Emergent Biosolutions (EBS) United States $2.378B 8.55
Myovant Sciences (MYOV) United Kingdom $1.780B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.529B 0.00
Zymeworks (ZYME) Canada $0.908B 0.00
Ambrx Biopharma (AMAM) United States $0.407B 0.00
SQZ Biotechnologies (SQZ) United States $0.345B 0.00
Enzo Biochem (ENZ) United States $0.164B 16.09